Skip to content
2000
Volume 9, Issue 3
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

By virtue of their RNA degrading catalytic activity, ribonucleases are potentially cytotoxic. For the application of these enzymes as therapeutics, however, they have to overcome several obstacles whose interplay is not yet fully understood. Ribonucleases with a basic pI are not only able to interact with the (negatively charged) cellular membrane but they are also distinctively selective for tumor cells. After the (endocytotic) uptake into the cell and release into the cytosol from the endosomes where they have to resist the attack by proteases, they face the cytosolic ribonuclease inhibitor. Only if they are able to evade the tight binding to the inhibitor (or if enough ribonuclease molecules enter the cell to neutralize the inhibitor protein) they are able to attack their target RNA, for which a sufficient ribonucleolytic activity is indispensable. Each of these steps can turn into an insurmountable hurdle spoiling the cytotoxic potential of these enzymes. In the present review I will summarize the status quo of the knowledge on the mechanisms and their interdependence as well as to develop strategies to overcome possible limitations.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920108784567263
2008-06-01
2025-08-18
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920108784567263
Loading

  • Article Type:
    Research Article
Keyword(s): antitumor; cytotoxicity; internalization; Ribonuclease; stability; therapeutic
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test